[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@arcellx Avatar @arcellx Arcellx

Arcellx's Chief Scientific Officer, Heba Nowyhed PhD, was named the CSO Award winner at the S.F. Business Times C-Suite Leaders Awards, recognizing her leadership and passion for biotech innovation. The company is also presenting new data at ASH25 from its Imagine-1 study of anito-cel in patients with relapsed or refractory multiple myeloma. Additionally, Arcellx will be attending IMS25, where its medical affairs team will be available to discuss its lead clinical asset.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXX%

Social topic influence philosophy 4.55%, trust 4.55%, ceo 4.55%, $aclx #4

Top accounts mentioned or mentioned by @kitepharma @ramielghandour @biotechtv @ehahematology @sfbusinesstimes @rami @ftlive @hrdotcom @gileadsciences @endptsalong @cindyperettiefor @checkorphan @stream_rx @mriramos

Top assets mentioned Arcellx, Inc. Common Stock (ACLX)

Top Social Posts

Top posts by engagements in the last XX hours

"Today we announced new positive data from our Phase X pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory #multiplemyeloma. Read the full press release: Anito-cel is partnered with @KitePharma. #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd"
X Link 2025-12-06T19:03Z XXX followers, XXX engagements

"Yesterday evening we announced new positive data from our Phase X pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma demonstrating anito-cel's potential to be a best-in-class treatment option.Anito-cel is partnered with @KitePharma . Read the full press release here: Today at 5:30 p.m. (PT) in Pacific Ballroom Salons 24-26 Ciara Freeman M.D. Ph.D. will present these preliminary results during an oral presentation. #RRMM #AnitoCel #CellTherapy #CancerResearch"
X Link 2024-12-09T16:36Z XXX followers, XXX engagements

"Attending #IMS25 Visit our Medical Affairs team at booth #616 in Hall E to learn more about our lead clinical asset anito-cel in late-stage development for the treatment of patients with relapsed or refractory #multiplemyeloma in collaboration with @KitePharma"
X Link 2025-09-16T21:38Z XXX followers, XXX engagements

"On November X Chief Operating Officer Aileen Fernandes will join industry leaders during the In pursuit of funding how to create a strategy to advance early-stage drug development panel discussion with @ftlive. This conversation will explore strategies on how #biotech companies can secure funding and stand out among competitors. To register: #MedEd"
X Link 2025-10-27T17:13Z XXX followers, XXX engagements

"Were pleased to announce our presentations at #ASH25 new data from our iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma and an analysis of geographic variation and systemic inequities of CAR-T therapy access in multiple myeloma in the U.S. Stop by our Medical Affairs booth to learn more about our novel binder the D-Domain. We are excited to engage with the hematology community and share insights that could help advance patient care in multiple myeloma. #CellTherapy #MultipleMyeloma #RRMM #AnitoCel #CancerResearch #Innovation"
X Link 2025-11-03T14:13Z XXX followers, 1272 engagements

"After leading teams at Fortune XXX companies Chief People Officer Kate Aiken took a leap into the startup world bringing her leadership philosophy with her. In this interview with @HRdotcom Kate discusses how she builds trust and what shaped her as a leader in HR. Read more: #CSuite #ThoughtLeadership"
X Link 2025-11-05T16:04Z XXX followers, XXX engagements

"Happy Thanksgiving At Arcellx we are grateful for the patients and physicians who participate in our clinical trials our amazing team members our partners at @KitePharma/@GileadSciences and our shareholders. Wishing everyone a joyful holiday"
X Link 2025-11-27T15:00Z XXX followers, XXX engagements

"Arcellx will present new iMMagine-1 data at #ASH25. We look forward to engaging with physicians and advocates sharing insights that could help advance patient care in #multiplemyeloma. Read the release: #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd"
X Link 2025-12-03T15:01Z XXX followers, XXX engagements

"Want to learn more about the data we presented at ASH Tomorrow our CEO @RamiElghandour is joining @endptsalong with EVP and Global Head of @KitePharma@cindy_perettiefor a fireside chat to discuss anito-cel as a potential treatment option for multiple myeloma patients. Register here: #MedEd"
X Link 2025-12-09T21:49Z XXX followers, XXX engagements

"Our Investor Relations event is live A panel of clinician experts are discussing the latest data from the Phase X pivotal iMMagine-1 study in patients with relapsed or refractory multiple myeloma. Tune in: #Investors $ACLX"
X Link 2025-12-07T01:05Z XXX followers, XXX engagements